GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tarsus Pharmaceuticals Inc (NAS:TARS) » Definitions » Mohanram G-Score

Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Mohanram G-Score : N/A (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Tarsus Pharmaceuticals Mohanram G-Score?

Tarsus Pharmaceuticals does not have enough data to calculate Mohanram G-Score.


Tarsus Pharmaceuticals Mohanram G-Score Historical Data

The historical data trend for Tarsus Pharmaceuticals's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tarsus Pharmaceuticals Mohanram G-Score Chart

Tarsus Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Mohanram G-Score
Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Tarsus Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Tarsus Pharmaceuticals's Mohanram G-Score

For the Biotechnology subindustry, Tarsus Pharmaceuticals's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tarsus Pharmaceuticals's Mohanram G-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where Tarsus Pharmaceuticals's Mohanram G-Score falls into.



Tarsus Pharmaceuticals Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Tarsus Pharmaceuticals  (NAS:TARS) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


Tarsus Pharmaceuticals Mohanram G-Score Related Terms

Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's Mohanram G-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03 is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Executives
Bobak R. Azamian director, 10 percent owner, officer: President and CEO 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Jose M. Trevejo officer: Chief Medical Officer C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Andrew D. Goldberg director 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Dianne C. Whitfield officer: Chief Human Resources Officer 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Bryan Wahl officer: General Counsel 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Elizabeth Yeu Lin director 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aziz Mottiwala officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Jeffrey S Farrow officer: See Remarks TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Leonard M. Greenstein officer: Chief Financial Officer 24562 BELGREEN PLACE, LAKE FOREST CA 92630
Seshadri Neervannan officer: Chief Operating Officer 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Mark J. Holdbrook officer: V.P., Clinical Affairs 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Michael Ackermann director, 10 percent owner 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Rosemary A Crane director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873